Despite being Pivotal for Decision-making, Real-World Evidence (RWE) Remains Underused in HTA
RWE is often assigned a low evidence grade by HTA bodies due to methodological limitations such as selection bias, missing data, and limited external validity.
These issues are for a large part driven by patient-related factors: limited trust due to lack of control over data sharing reduces participation, while high dropout rates—caused by fatigue, poor usability, disease burden, and lack of feedback or incentives—undermine data completeness and representativeness.
MyOwnData makes studies more inclusive and representative through low-treshold to participation from easy accessibility to trials for study participants (patients).
Transmineo designed MyOwnData’s platform applying proven technologies in a new, patient-centric way to generate decision-grade RWE —now essential for lifecycle management, especially in orphan drugs.
Reliable RWE depends not only on data quality, but on representative patient populations in real-world treatment settings. Yet, limited trust in pharmaceutical companies can restrict access to patient data, leading to participation bias and underrepresentation of key groups. This ultimately weakens evidence and can delay or limit patient access to therapies.
MyOwnData addresses this by giving patients full control over their data while ensuring high-quality, representative RWE. Through tailored, user-friendly designs co-created with patients, the platform drives strong engagement and retention across diverse patient populations.
